Literature DB >> 12543669

Effect of amphotericin B on larval growth of Echinococcus multilocularis.

Stefan Reuter1, Marion Merkle, Klaus Brehm, Peter Kern, Burkhard Manfras.   

Abstract

Alveolar echinococcosis is caused by the parasitic cestode Echinococcus multilocularis. Benzimidazoles, namely, mebendazole and albendazole, are the only drugs available for the treatment of inoperable alveolar echinococcosis. At present, no therapeutic alternative is available for patients with progressive disease under treatment or for patients who are unable to tolerate the side effects of the benzimidazoles. In addition, benzimidazoles are only parasitostatic for E. multilocularis. Thus, new therapeutic options are of paramount importance. In the present study we examined the in vitro effect of amphotericin B on E. multilocularis larvae. E. multilocularis metacestodes grown in the peritoneal cavities of Mongolian gerbils were transferred into a culture system. Vesicles budded from the tissue blocks and increased in number and size during the first 5 weeks. After 6 weeks drugs were added and deleterious effects on the vesicles were observed macroscopically and microscopically. By use of this in vitro tissue culture model we demonstrated that amphotericin B effectively inhibits the growth of E. multilocularis metacestodes. This destructive effect was significantly more rapid with amphotericin B than with the benzimidazoles. Cyclic treatment was effective in suppressing parasite growth. However, amphotericin B appears to be parasitostatic for E. multilocularis larvae, and regrowth occurs even after extended periods. In summary, amphotericin B constitutes the first promising alternative for the treatment of alveolar echinococcosis in cases of intolerance or resistance to benzimidazoles. It holds promise as an effective treatment option for otherwise fatal courses of disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12543669      PMCID: PMC151734          DOI: 10.1128/AAC.47.2.620-625.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

1.  Efficacies of albendazole sulfoxide and albendazole sulfone against In vitro-cultivated Echinococcus multilocularis metacestodes.

Authors:  K Ingold; P Bigler; W Thormann; T Cavaliero; B Gottstein; A Hemphill
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Effect of albendazole on recurrent and residual alveolar echinococcosis of the liver after surgery.

Authors:  H Ishizu; J Uchino; N Sato; S Aoki; K Suzuki; H Kuribayashi
Journal:  Hepatology       Date:  1997-03       Impact factor: 17.425

3.  In vitro activities of benzimidazoles against Echinococcus multilocularis metacestodes.

Authors:  H Jura; A Bader; M Frosch
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics of systemic antifungal drugs.

Authors:  T K Daneshmend; D W Warnock
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

5.  Guidelines for treatment of cystic and alveolar echinococcosis in humans. WHO Informal Working Group on Echinococcosis.

Authors: 
Journal:  Bull World Health Organ       Date:  1996       Impact factor: 9.408

Review 6.  Benzimidazoles in the treatment of alveolar echinococcosis: a comparative study and review of the literature.

Authors:  S Reuter; B Jensen; K Buttenschoen; W Kratzer; P Kern
Journal:  J Antimicrob Chemother       Date:  2000-09       Impact factor: 5.790

7.  Hepatic tissue culture model for study of host-parasite interactions in alveolar echinococcosis.

Authors:  H Jura; A Bader; M Hartmann; H Maschek; M Frosch
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

8.  In vitro and in vivo activity of amphotericin B-lipid formulations against experimental Trypanosoma cruzi infections.

Authors:  V Yardley; S L Croft
Journal:  Am J Trop Med Hyg       Date:  1999-08       Impact factor: 2.345

9.  Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model.

Authors:  R E Lewis; B C Lund; M E Klepser; E J Ernst; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

Review 10.  Long-term mebendazole therapy may be parasitocidal in alveolar echinococcosis.

Authors:  R W Ammann; A Fleiner-Hoffmann; F Grimm; J Eckert
Journal:  J Hepatol       Date:  1998-12       Impact factor: 25.083

View more
  22 in total

1.  In vitro activities of itraconazole, methiazole, and nitazoxanide versus Echinococcus multilocularis larvae.

Authors:  Stefan Reuter; Burkhard Manfras; Marion Merkle; Georg Härter; Peter Kern
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Mitochondrial ribosome as the target for the macrolide antibiotic clarithromycin in the helminth Echinococcus multilocularis.

Authors:  Alexander Mathis; Peter Wild; Erik C Boettger; Christian M O Kapel; Peter Deplazes
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  In vitro efficacy of dicationic compounds and mefloquine enantiomers against Echinococcus multilocularis metacestodes.

Authors:  Britta Stadelmann; Tatiana Küster; Sabrina Scholl; Fabienne Barna; Christian Kropf; Jennifer Keiser; David W Boykin; Chad E Stephens; Andrew Hemphill
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

4.  In vitro and in vivo efficacies of mefloquine-based treatment against alveolar echinococcosis.

Authors:  Tatiana Küster; Britta Stadelmann; Corina Hermann; Sabrina Scholl; Jennifer Keiser; Andrew Hemphill
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

5.  Gerbu adjuvant modulates the immune response and thus the course of infection in C56BL/6 mice immunised with Echinococcus multilocularis rec14-3-3 protein.

Authors:  Maxi Margos; Bruno Gottstein
Journal:  Parasitol Res       Date:  2010-05-19       Impact factor: 2.289

6.  In vitro efficacy of triclabendazole and clorsulon against the larval stage of Echinococcus multilocularis.

Authors:  David Richter; Joachim Richter; Beate Grüner; Kathrin Kranz; Juliane Franz; Peter Kern
Journal:  Parasitol Res       Date:  2013-02-28       Impact factor: 2.289

7.  Salvage treatment with amphotericin B in progressive human alveolar echinococcosis.

Authors:  Stefan Reuter; Andreas Buck; Olaf Grebe; Karin Nüssle-Kügele; Peter Kern; Burkhard J Manfras
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

8.  It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug.

Authors:  Ana C Mesa-Arango; Liliana Scorzoni; Oscar Zaragoza
Journal:  Front Microbiol       Date:  2012-08-08       Impact factor: 5.640

9.  Bioinformatic prediction of epitopes in the Emy162 antigen of Echinococcus multilocularis.

Authors:  Yanhua Li; Xianfei Liu; Yuejie Zhu; Xiaotao Zhou; Chunbao Cao; Xiaoan Hu; Haimei Ma; Hao Wen; Xiumin Ma; Jian-Bing Ding
Journal:  Exp Ther Med       Date:  2013-06-05       Impact factor: 2.447

10.  Comparison of Scolicidal Effects of Amphotricin B, Silver Nanoparticles,_and Foeniculum vulgare Mill on Hydatid Cysts Protoscoleces.

Authors:  Mohammad Reza Lashkarizadeh; Keivan Asgaripour; Ebrahim Saedi Dezaki; Majid Fasihi Harandi
Journal:  Iran J Parasitol       Date:  2015 Apr-Jun       Impact factor: 1.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.